New York S 488: Relates to campaign contributions by intermediaries

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S00488 Summary:

BILL NOS00488A

&nbsp

SAME ASSAME AS A02289-A

&nbsp

SPONSORFERNANDEZ

&nbsp

COSPNSRADDABBO, JACKSON, WEBB

&nbsp

MLTSPNSR

&nbsp

Add 396-rrr, Gen Bus L

&nbsp

Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

Go to top S00488 Actions:

BILL NOS00488A

&nbsp

01/08/2025REFERRED TO CONSUMER PROTECTION

01/28/20251ST REPORT CAL.204

02/03/20252ND REPORT CAL.

02/04/2025ADVANCED TO THIRD READING 

02/25/2025PASSED SENATE

02/25/2025DELIVERED TO ASSEMBLY

02/25/2025referred to consumer affairs and protection

05/22/2025RECALLED FROM ASSEMBLY

05/22/2025returned to senate

05/22/2025VOTE RECONSIDERED - RESTORED TO THIRD READING

05/22/2025AMENDED ON THIRD READING 488A

06/09/2025REPASSED SENATE

06/09/2025DELIVERED TO ASSEMBLY

06/09/2025referred to consumer affairs and protection

01/07/2026died in assembly

01/07/2026returned to senate

01/07/2026REFERRED TO CONSUMER PROTECTION

05/12/2026REPORTED AND COMMITTED TO RULES

05/12/2026ORDERED TO THIRD READING CAL.1005

05/12/2026PASSED SENATE

05/12/2026DELIVERED TO ASSEMBLY

05/12/2026referred to consumer affairs and protection

Go to topS00488 Committee&nbspVotes:

Go to topS00488 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS00488 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 488--A
 Cal. No. 204

 2025-2026 Regular Sessions

 IN SENATE

 (Prefiled)

 January 8, 2025
 ___________

 Introduced by Sens. FERNANDEZ, ADDABBO, WEBB -- read twice and ordered
 printed, and when printed to be committed to the Committee on Consumer
 Protection -- reported favorably from said committee, ordered to first
 and second report, ordered to a third reading, passed by Senate and
 delivered to the Assembly, recalled, vote reconsidered, restored to
 third reading, amended and ordered reprinted, retaining its place in
 the order of third reading

 AN ACT to amend the general business law, in relation to requiring
 prescription drug manufacturers to notify the attorney general of
 arrangements between pharmaceutical manufacturers resulting in the
 delay of the introduction of generic drugs

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. This act shall be known and may be cited as the "manufac-
 2 turer disclosure and transparency act".
 3 § 2. The general business law is amended by adding a new section 396-
 4 rrr to read as follows:
 5 § 396-rrr. Delay of introduction of generic medications. 1. For
 6 purposes of this section, the following terms shall have the following
 7 meanings:
 8 (a) "Agreement" means anything that would constitute an agreement
 9 under state law.
 10 (b) "Attorney general" means the office of the New York state attorney
 11 general.
 12 (c) "Patent settlement agreement" means any agreement that is entered
 13 into within sixty days of the resolution or the settlement of patent
 14 litigation, or any other agreement that is contingent upon, provides a
 15 contingent condition for, or is otherwise related to the resolution or
 16 settlement of patent litigation, including, without limitation:

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD00774-04-5

 S. 488--A 2

 1 (i) any agreement required to be provided to the federal trade commis-
 2 sion or the antitrust division of the United States department of
 3 justice under the Medicare Prescription Drug, Improvement, and Modern-
 4 ization Act of 2003, Pub. L. No. 108-173;
 5 (ii) any agreement between a biosimilar or interchangeable product
 6 applicant and a biological product deemed a reference product sponsor
 7 under the Biologics Price Competition and Innovation Act of 2009, Pub.
 8 L. No. 111-148, that resolves patent claims between the applicant and
 9 sponsor; or
 10 (iii) any agreement between parties to a patent settlement agreement
 11 executed sixty days before or after final execution of the patent
 12 settlement agreement and which either: (A) is intended to relate to the
 13 patent settlement agreement, suc